Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 5/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.40 |
| ▸ | IP6K3 | Q96PC2 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31183111 | 0.79 | HCAR3 (0.39) | CSNK2A2CSNK2BKDM4ENPC1RAB9A | |
| SCHEMBL86743 | 0.75 | NOS2 (0.48) | KDM4ENPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL11582786 | 0.72 | FGFR1 (0.50) | KDM4ENPC1RAB9ASMN1; SMN2MEN1 | |
| Water SCHEMBL11581337 | 0.71 | FGFR1 (0.49) | KDM4ENPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL31137383 | 0.71 | TDP1 (0.47) | KDM4ENPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL31137202 | 0.71 | TDP1 (0.43) | KDM4ENPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL28208128 | 0.71 | KDM4E (0.48) | KDM4ENPC1RAB9ASMN1; SMN2MEN1 | |
| Doqualast SCHEMBL124450 | 0.69 | KDM4E (0.63) | KDM4ENPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL11268488 | 0.69 | ALDH1A1 (0.62) | KDM4ERAB9AMEN1KMT2AGAA | |
| SCHEMBL27180283 | 0.68 | GRIN2D (0.51) | CSNK2A1KDM4ENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125380-A1 | PRMT5 INHIBITORS AND METHODS OF USE | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4592289-A1 | NOVEL PRMT5 INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-20250051331-A1 | PRMT5 INHIBITORS AND METHODS OF USE | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2025-02-13 | — | — | US | disclosed |
| US-12173002-B2 | PRMT5 inhibitors and methods of use | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-12-24 | — | — | US | disclosed |
| US-20240294528-A1 | PRMT5 INHIBITORS AND METHODS OF USE | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12173002-B2 | PRMT5 inhibitors and methods of use | PRMT5, PRMT1, PRMT7 | CSNK2A2 1306/4885CSNK2B 1146/4885CSNK2A1 1215/4885 |
| US-20250051331-A1 | PRMT5 INHIBITORS AND METHODS OF USE | PRMT5, PRMT1, PRMT7 | CSNK2A2 1174/4885CSNK2B 846/4885CSNK2A1 1096/4885 |
| US-20260125380-A1 | PRMT5 INHIBITORS AND METHODS OF USE | PRMT1, PRMT5, PRMT6 | CSNK2A2 171/4885CSNK2B 172/4885CSNK2A1 111/4885 |
| US-20240294528-A1 | PRMT5 INHIBITORS AND METHODS OF USE | PRMT5, PRMT1, PRMT3 | CSNK2A2 1606/4885CSNK2B 1465/4885CSNK2A1 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.